Window of opportunity clinical trial designs to study cancer metabolism

Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer Jg. 122; H. 1; S. 45 - 51
Hauptverfasser: Aroldi, Francesca, Lord, Simon R.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 01.01.2020
Nature Publishing Group
Schlagworte:
631/154
631/67
631/67/2327
Antidiabetics
Biological activity
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cancer therapies
Clinical trials
Clinical Trials as Topic - methods
Drug development
Drug metabolism
Drug Repositioning - methods
Drug Resistance
Epidemiology
Humans
Metabolism
Metabolomics
Metformin
Metformin - therapeutic use
Mitochondria
Molecular Medicine
Neoplasms - drug therapy
Neoplasms - metabolism
Oncology
Pharmacodynamics
Research Design
Review
Review Article
Time-to-Treatment
Tumors
ISSN:0007-0920, 1532-1827, 1532-1827
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic assessment of a therapy of interest in tumours that are unperturbed by prior treatment. Many of the first window trials interrogated the bioactivity of drugs being repurposed for cancer treatment, in particular the anti-mitochondrial agent, metformin. In this review, we describe examples of window study designs that have been used to assess drugs that target cancer metabolism with a focus on metformin. In addition, we discuss how window studies may aid the development of molecular metabolic cancer imaging.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-019-0621-4